BioNTech Stock Falls 21% Over Turning To Loss In Q4, Weak FY26 Outlook, Co-Founders Plan To Exit

Shares of BioNTech plunged ~22% intraday after the company reported a fourth-quarter net loss and co-founders Ugur Sahin and Özlem Türeci announced plans to establish an independent biotechnology company. The move raises concerns about near-term company fundamentals and strategic uncertainty from founders' departure into a separate venture, driving heavy selling pressure.

Analysis

Shares of BioNTech plunged ~22% intraday after the company reported a fourth-quarter net loss and co-founders Ugur Sahin and Özlem Türeci announced plans to establish an independent biotechnology company. The move raises concerns about near-term company fundamentals and strategic uncertainty from founders' departure into a separate venture, driving heavy selling pressure.